Dark

Check out our API

EARS
Auris Medical Holding Ltd. Common Shares 0.01 SF (Bermuda)
stock NASDAQ

Inactive

Jul 23, 2021

3.05USD-1.774%(-0.06)174,066

Pre-market

0.00USD-100.000%(-3.10)0

After-hours

0.00USD0.000%(0.00)0

OverviewHistoricalExchangesShortsNews

Jul 16, 2021

09:00AM EDT Auris Medical Announces Launch of New Corporate Website GlobeNewswire Inc

Jul 14, 2021

11:40AM EDT Auris Medical's Bentrio Nasal Spray Shows Encouraging Preclinical Action In Prevention, Mitigation Of COVID-19 Benzinga

09:04AM EDT Auris Medical Highlights Publication Of Data From Preclinical Studies With Bentrio Nasal Spray In Prevention And Mitigation Of SARS-CoV-2 Showing 'Up to 99% reduction of SARS-CoV-2 viral titer with prophylactic treatment vs. controls' Benzinga

09:02AM EDT -- Bentrio formulation well tolerated in vitro on human nasal epithelium -- Up to 99% reduction of SARS-CoV-2 viral titer with prophylactic treatment vs. controls -- Viral titer reduced 12- or 14-fold vs. controls when treatment started 24 or 30 h post infection GlobeNewswire Inc

Jul 6, 2021

09:01AM EDT Auris Medical To Develop KRAS-Targeting RNA Treatment For Colorectal Cancer As First Therapeutic Indication For OligoPhore Technology Benzinga

09:00AM EDT -- Treatment of KRAS-driven colorectal cancer selected as first therapeutic indication for OligoPhore platform -- Company to launch development program under project code AM-401 with aim of IND submission in late 2022 GlobeNewswire Inc

Jun 28, 2021

08:32AM EDT Auris Medical To Initiate Market Launch Of Bentrio Nasal Spray In Germany Benzinga

08:30AM EDT Auris Medical to Initiate Market Launch of GlobeNewswire Inc

Jun 21, 2021

10:28AM EDT Auris Medical Stock Trading Higher After OligoPhore Technology Shows Tumor Inhibition In Animal Studies Benzinga

08:30AM EDT -- Treatment with OligoPhoreTM siRNA stops aggressive ATLL tumor growth to near zero -- Significant reduction in tumor size, spleen size and peripheral blood lymphocyte counts -- Results add to extensive body of evidence for effective OligoPhoreTM enabled delivery of nucleic acids to extrahepatic tissues GlobeNewswire Inc

Jun 3, 2021

09:17AM EDT Auris Medical Enters RNA Therapeutics with Trasir Therapeutics Acquisition; Plans To Spin-Off/Divest Existing Programs Benzinga

08:24AM EDT Auris Medical Acquires RNA Therapeutics Company Trasir RTTNews

08:23AM EDT The Daily Biotech Pulse: Merck Completes Organon Spin-Off, Auris Repositions As RNA Therapeutic Company With Trasir Purchase, Replimune's Readout Benzinga

07:44AM EDT Auris Medical Announces Acquisition Of Privately Held Trasir Therapeutics RTTNews

07:32AM EDT Auris Medical Acquires Trasir Therapeutics; Purchase Price Comprises Of 0.77M Shares Benzinga

07:30AM EDT Auris Medical Announces Acquisition of RNA Therapeutics Company GlobeNewswire Inc

Jun 1, 2021

08:38AM EDT Auris Medical Says Starting Preparations For COVID-19 Trial With Bentrio in India Benzinga

08:30AM EDT Auris Medical Starts Preparations for Covid-19 Trial with Bentrio GlobeNewswire Inc

May 28, 2021

08:30AM EDT Auris Medical Holding to Present at LD Micro Invitational XI GlobeNewswire Inc

May 25, 2021

09:07AM EDT Auris Medical Announces Completion Of Bentrio Conformity Assessment Procedure For Marketing In EU Benzinga

09:00AM EDT -- Meeting essential requirements for marketing BentrioTM in Europe under CE mark -- On track for first product launch in Europe towards end of Q2 2021 GlobeNewswire Inc

May 14, 2021

08:37AM EDT Auris Medical Reaches Midpoint For Enrollment In Part B Of AM-125 Phase 2 TRAVERS Trial In Acute Peripheral Vertigo Benzinga

08:30AM EDT Auris Medical Reaches Midpoint for Enrollment in Part B of AM-125 GlobeNewswire Inc

May 7, 2021

03:01PM EDT Auris Medical Stock Is Trading Higher As Bentrio Hit Primary Endpoint Goal In Allergic Rhinitis Study Benzinga

09:06AM EDT Auris Medical Says Meets Primary Efficacy Endpoint In Clinical Evaluation In Allergic Rhinitis Benzinga

09:05AM EDT -- BentrioTM meets primary efficacy endpoint in clinical evaluation in allergic rhinitis -- Clinically relevant and significant reduction in nasal symptoms -- Superior efficacy ratings by patients and clinicians -- Pre-submission meeting with FDA supports 510(k) regulatory pathway GlobeNewswire Inc

Apr 13, 2021

08:16AM EDT The Daily Biotech Pulse: Leadership Transition At Amarin, Vaccine Setback For J&J, FDA Nod For Label Expansion of Roche's Asthma Drug Benzinga

07:45AM EDT Auris Medical Announces Positive Preclinical and Clinical Outcomes with AM-301 and Details Plans for Market Launch Benzinga

07:45AM EDT -- Clinical evaluation of AM-301 nasal spray in allergic rhinitis meets primary endpoint -- Extended protection achieved over several hours -- Preliminary preclinical data suggest therapeutic utility post SARS-CoV-2 infection -- Product launch under BentrioTM brand in selected European countries towards end of Q2 2021 GlobeNewswire Inc

Apr 10, 2021

09:19AM EDT The Week Ahead In Biotech (April 11-17): Avenue Therapeutics FDA Decision and Conference Presentations In The Spotlight Benzinga

Apr 8, 2021

08:02AM EDT Auris Medical To Provide Business Update On AM-301 Program On April 13, 2021 Benzinga

08:00AM EDT Auris Medical to Provide Business Update on AM-301 Program on GlobeNewswire Inc

Mar 31, 2021

09:59AM EDT Auris Medical shares were trading lower after the company reported FY20 earnings results. Benzinga

08:31AM EDT Auris Medical FY20 EPS $(1.36), Up From $(2.28) YoY Benzinga

08:30AM EDT -- Clinical evaluation of AM-301 nasal spray in allergen protection progressing -- Launch of AM-301 expected in selected markets towards the end of second quarter 2021 -- Phase 2 trial with AM-125 in acute vertigo expected to complete enrollment in third quarter 2021 -- Equity and cash position significantly strengthened -- Strategy review ongoing GlobeNewswire Inc

04:26AM EDT Earnings Scheduled For March 31, 2021 Benzinga

Mar 24, 2021

08:00AM EDT Auris Medical to Report Second Half and Full Year 2020 Financial GlobeNewswire Inc

Mar 9, 2021

10:18AM EST Mid-Morning Market Update: Markets Open Higher; Dicks Sporting Goods Profit Beats Views Benzinga

10:05AM EST Auris Medical Holding Ltd. (EARS) shares are rising more than 33 percent on Tuesday morning trade as the clinical-stage company announced the initiation of a clinical investigation of AM-301 in allergic rhinitis with its affiliate Altamira Medica AG. RTTNews

Jan 29, 2021

08:39AM EST Auris Medical Begins Clinical Investigation Of AM-301 In Allergic Rhinitis RTTNews

08:34AM EST Auris Medical Announces Initiation Of Clinical Investigation Of AM-301 In Allergic Rhinitis Benzinga

08:30AM EST Hamilton, Bermuda, January 29, 2021 Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology, rhinology and allergy and CNS disorders, today announced with its affiliate Altamira Medica AG the initiation of a clinical investigation of AM-301 in allergic rhinitis. GlobeNewswire Inc

Dec 15, 2020

08:37AM EST Auris Medical Expects To Meet Requirements For CE Marking, A Prerequisite For Commercializing AM-301 In Europe, In Q2 Of 2021 Benzinga

08:30AM EST -- Net cash inflow of $13.4 million from recent registered direct offering and warrant exercises -- AM-301 program progressing towards clinical and regulatory milestones -- Strategy review ongoing GlobeNewswire Inc

Dec 7, 2020

04:10PM EST Auris Medical Holding to Present at the 13th Annual LD Micro Main GlobeNewswire Inc

Dec 2, 2020

02:31PM EST Mid-Afternoon Market Update: Dow Edges Higher; Sequential Brands Shares Spike Higher Benzinga

02:27PM EST Mid-Day Market Update: Crude Oil Rises 3%; Ovid Therapeutics Shares Plummet Benzinga

08:58AM EST Auris Medical Holding Prices $8 Mln Common Shares Offering RTTNews

08:45AM EST Auris Medical Holding Ltd. Prices $8,000,000 Common Shares GlobeNewswire Inc

07:35AM EST The Daily Biotech Pulse: Pfizer-BioNTech Vaccine Gets Temporary UK Authorization, Ovid's Trial Disappointment, Vanda Snags FDA Nod Benzinga

Dec 1, 2020

09:06AM EST UPDATE: Auris Medical Reports AM-301 Data, Says Up To 99.4% Reduction Of Viral Titer In Human Epithelial Cell Culture Benzinga

09:00AM EST Auris Medical Reports Positive In Vitro Efficacy Data For AM-301 In Protecting Against Sars-CoV-2 Infection Benzinga

09:00AM EST -- Up to 99.4% reduction of viral titer in human epithelial cell culture (p<0.001) -- Results suggest potential for AM-301 nasal spray to mitigate risk of Sars-CoV-2 infection GlobeNewswire Inc

Nov 25, 2020

03:35PM EST Auris Medical Receives Notice Of Allowance For U.S. Patent Titled 'METHODS FOR THE TREATMENT OF TINNITUS INDUCED BY COCHLEAR EXCITOTOXICITY' Benzinga

Nov 20, 2020

09:10AM EST Auris Medical Launches Website for AM-301-focused Subsidiary, GlobeNewswire Inc

Oct 13, 2020

02:38PM EDT Mid-Afternoon Market Update: Dow Falls 200 Points; Gossamer Bio Shares Plummet Benzinga

10:36AM EDT Why Auris Medical's Stock Is Trading Higher Today Benzinga

09:04AM EDT Auris Medical Announces Initiation Of Part B Of TRAVERS Phase 2 Study With AM-125 In Vertigo Benzinga

09:00AM EDT Auris Medical Announces Initiation of Part B of TRAVERS Phase 2 GlobeNewswire Inc

08:18AM EDT CORRECTION: Johnson & Johnson Sued Over Payouts Regarding Acquisition Of Auris Health; Co. Is Not Related to Auris Medical Benzinga

Oct 6, 2020

05:16PM EDT Auris Medical Files To Sell 2.21M Share Common Stock Offering Benzinga

Sep 18, 2020

01:03PM EDT Earnings Recap For The Week Of September 18 Benzinga

Sep 17, 2020

08:16AM EDT Auris Medical Holding H1 Net Loss CHF 2.7 Mln Or CHF 0.58 Per Share RTTNews

08:11AM EDT Auris Medical Holding Says Review Of Strategic Options Initiated; Board Has Started A Process To Explore, Review And Evaluate A Broad Range Of Potential Strategic Alternatives Including Sale Or Merger Of Company Benzinga

08:00AM EDT -- Advancing Phase 2 trial with AM-125 in acute vertigo based on positive interim data -- Positive outcome from AM-201 trial in prevention of antipsychotic-induced weight gain -- Addition of new intranasal program with development of drug-free spray for protection against airborne pathogens and allergens -- Review of strategic options initiated GlobeNewswire Inc

04:04AM EDT Earnings Scheduled For September 17, 2020 Benzinga

Sep 11, 2020

08:00AM EDT Auris Medical to Report First Half 2020 Financial Results and GlobeNewswire Inc

Sep 8, 2020

08:31AM EDT Auris Medical Highlights Launch Of Drug-Free Nasal Spray For Protection Against Airborne Pathogens, Allergens Benzinga

08:30AM EDT -- Development of AM-301 nasal spray initiated with aim of regulatory submission in 2021 -- Key component of AM-301 shown to reduce SARS-CoV-2 viral infectious load in vitro by up to 99% -- Creation of dedicated subsidiary, Altamira Medica Ltd, to focus solely on AM-301 development program -- CHF 1.5 m convertible loan arranged in support of development program GlobeNewswire Inc

Sep 3, 2020

08:34AM EDT Auris Medical Announces Interim Data From TRAVERS Phase 2 Study With AM-125 in Vertigo; Says Improvement 1.9 To 2.4 Times Greater With Highest Dose Than With Placebo Benzinga

08:33AM EDT Auris Medical Announces Positive Interim Data From TRAVERS Phase 2 Study With AM-125 In Vertigo RTTNews

08:30AM EDT -- Dose dependent improvement in balance tests over placebo in Part A of TRAVERS trial -- Improvement 1.9 to 2.4 times greater with highest dose than with placebo -- Trial to proceed with Part B to test AM-125 10 and 20 mg vs. placebo GlobeNewswire Inc

Aug 20, 2020

04:32PM EDT Auris Medical Regains Listing Compliance With NASDAQ Minimum Bid Requirement Benzinga

04:30PM EDT Auris Medical Regains Listing Compliance with NASDAQ Minimum Bid GlobeNewswire Inc

Jul 29, 2020

08:40AM EDT Auris Medical Announces Completion Of Enrollment Into First Part Of TRAVERS Phase 2 Study With AM-125 In Vertigo Benzinga

08:30AM EDT -- Dose escalation completed as last patient enrolled into Part A of TRAVERS study -- Interim results to be announced in Q3 of 2020 GlobeNewswire Inc

Share